NHS to offer 'groundbreaking' sickle cell therapy

NHS England to offer Casgevy for sickle cell disease patients
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by approval for transfusion-dependent beta-thalassemia (TDT) in January 2024. NHS England reached an earlier reimbursement agreement for Casgevy in TDT in August 2024.
Sickle cell gene therapy Casgevy finally cleared for NHS use
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme and with a confidential discount.
Sickle cell disease ‘cure’ to be offered to NHS patients
Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant
NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease
The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) gene therapy to treat a severe form of sickle cell disease (SCD).
NHS to offer 'groundbreaking' sickle cell therapy as patients given 'very real prospect of cure'
A groundbreaking £1.65million gene therapy treatment offering hope for sickle cell disease patients has been approved for use on the NHS in England. The one-time treatment, called Casgevy (exa-cel), has shown remarkable success in clinical trials,
UK NHS to offer £1.65million 'groundbreaking' sickle cell gene therapy
A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely to receive it, experts say.
Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients
Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with
'Groundbreaking' sickle cell treatment to be offered to NHS patients for first time
A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be eligible after the National Institute for Health and Care Excellence (Nice) approved Casgevy for some patients with the genetic condition.
UK health system to offer cutting-edge gene therapy for sickle cell disease
Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care Excellence (NICE) said on Friday.
Gene-editing Therapy Could Be The Cure To Sickle Cell Disease
In 2019, the first CRISPR clinical trials were conducted to treat sickle cell diseases and in 2020, this treatment was injected directed into a human patient to treat hereditary blindness. The National Institute for Health and Care Excellence said it could suit around 50 patients per year.
Revolutionary gene-editing therapy for sickle cell approved
NHS Karla Sofia Gascón apologizes for old tweets, says she is 'deeply sorry to those I have caused pain' Everything we know about China's new 6th gen fighter jet... AstraZeneca cancels £450m investmen
Sickle cell patients share delight over approval of new treatment
NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...
People living with Sicke Cell apprehensive that new treatment Casgevy is here to stay
People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...
STAT2d
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...
Oxford Mail on MSN4h
Oxfordshire student to receive new sickle cell treatment
An Oxfordshire university student is among those set to receive a "transformative" gene-therapy treatment on the NHS for sickle ...